Roche announces positive data from Phase I obesity treatment trial

Roche has reported positive topline results from the Phase I CT-996-201 trial of CT-996, an oral GLP-1 receptor agonist for type 2 diabetes (T2D) and obesity. This trial, which is double-blind and placebo-controlled, has completed its initial arms in obese participants without T2D. The next phase will enroll 30 participants with both obesity and T2D in Q4 2024.

The trial aims to assess CT-996’s safety, tolerability, and its effects on body weight and glucose regulation. Initial results showed a 6.1% weight reduction in non-T2D participants over four weeks. CT-996 was well-tolerated, with mild to moderate gastrointestinal issues. The drug’s absorption was not affected by fasting or high-fat meals, suggesting flexible dosing. Following these results, CT-996 will progress to Phase II development.

Additionally, Roche’s Phase II/III SKYSCRAPER-06 trial of tiragolumab with Tecentriq (atezolizumab) and chemotherapy did not meet its primary endpoints for non-small cell lung cancer.